FRONTEO Launches Research Support Program to Provide “KIBIT Amanogawa” Medical Paper Search AI to Universities and Research Institutions for One Year

Launches “KIBIT Amanogawa for Academia Program” to Support Academic Research; Up to 10 Projects to Be Selected to Accelerate the Creation of Innovative Pharmaceuticals Originating in Japan

Tokyo, Japan, July 7, 2026 - FRONTEO, Inc. (Headquarters: Tokyo, Japan; President & CEO: Masahiro Morimoto; hereinafter “FRONTEO”), guided by the philosophy of “Restoring Japan’s Position as a Global Hub for Drug Discovery,” is launching the “KIBIT Amanogawa for Academia Program,” an academic research support initiative that provides universities and research institutions with a license to use its proprietary medical paper search AI system, “KIBIT Amanogawa,” for approximately one year.
Through this program, up to 10 projects will be selected to support drug discovery research in academia. By delivering the medical paper search AI "KIBIT Amanogawa"—which uncovers previously unrecognized links between genes and diseases from a vast body of papers—to research sites, the program aims to foster new ideas among researchers and contribute to the creation of innovative pharmaceuticals originating in Japan.

■Application Overview of the Academic Research Support Program "KIBIT Amanogawa for Academia Program"

■Background of This Program
As drug discovery research becomes increasingly sophisticated and specialized, the role played by universities and research institutions in the creation of innovative pharmaceuticals is growing ever more important. Guided by the philosophy of “Restoring Japan’s Position as a Global Hub for Drug Discovery,” FRONTEO has strengthened its collaboration with academic institutions^*1,2 and university-based biotech startups^*3 both in Japan and abroad through its AI-driven drug discovery support service, “Drug Discovery AI Factory (DDAIF)”^*4, which utilizes the company’s proprietary Equation-driven AI, “KIBIT”^*5.

This program supports researchers in generating new ideas and hypotheses by enabling the use of “KIBIT Amanogawa” in basic research conducted in academia, which plays a leading role in the earliest stages of drug discovery research.
FRONTEO aims to continue contributing to the creation of innovative pharmaceuticals originating in Japan by strengthening research capabilities in academia.

Notes:
*1 April 27, 2026, press release: FRONTEO and Science Tokyo establish industry-academia Collaborative Research Cluster for AI-driven drug discovery, https://legal.fronteousa.com/resources/pr/20260427
*2 May 13, 2026, press release: The University of Oklahoma confirms inhibition of cell proliferation with a novel candidate target molecule for pancreatic cancer discovered by FRONTEO's AI drug discovery support service DDAIF, https://legal.fronteousa.com/resources/pr/20260513_02
*3 February 12, 2026, press release: FRONTEO Launches “DDAIF Innovation Bridge” to Provide Scientific Support for Bio-Ventures Through Its AI-Driven Drug Discovery Support Service “Drug Discovery AI Factory”, https://legal.fronteousa.com/resources/pr/20260212_01
*4 DDAIF: An AI-driven drug discovery support service in which FRONTEO’s drug discovery experts, well-versed in both AI and drug discovery, leverage the natural language processing technology of FRONTEO’s proprietary AI “KIBIT” and its proprietary analytical methods to provide hypothesis generation for target molecule and indication discovery.
*5 Equation-driven AI “KIBIT”: An artificial intelligence independently developed by FRONTEO. By utilizing mathematical equations, KIBIT enables discontinuous discoveries, identification of causal relationships, and highly accurate, reproducible analyses. Its lightweight learning process enables fast, high-precision analysis on a single personal computer.

About KIBIT Amanogawa   https://lifescience.fronteo.com/products/amanogawa/
Introduction Video: https://youtu.be/lk2kBxLx7oM?si=h8KhAg4b6cr91YbH 

KIBIT Amanogawa system interface. The dots displayed on the “Space Map” in the upper-left corner represent individual academic papers.

"KIBIT Amanogawa" is a medical paper search AI system equipped with FRONTEO's proprietary natural language processing algorithm. It comprehensively analyzes more than 35 million publications and derives associations between genes and diseases not explicitly stated in published papers, through an approach called "discontinuous discovery."
Analysis results are visualized on a map, allowing the strength of associations and the positional relationships among papers to be grasped at a glance. This leads to encounters with findings that could not be reached through keyword searches, supporting researchers' hypothesis generation and new ideas.
It significantly reduces the vast amount of literature search work traditionally performed manually and enables comprehensive, unbiased analysis, allowing researchers to focus on their core research activities.

About FRONTEO, Inc. https://www.fronteo.com/en/